MedTrace Logo

Diagnostic Challenges in IC (and Male CPPS)

NCT00672087 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2020-08-04

No results posted yet for this study

Summary

The etiology and pathogenesis of interstitial cystitis (IC) and its related condition in men, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has remained elusive. This has hampered development of mechanistic treatment strategies for these common, chronic and distressing medical conditions. We believe that IC and perhaps CP/CPPS are a spectrum of complex but inter-related genetic and acquired diseases resulting from the interaction of several genes regulating immune/inflammatory and neurogenic parameters and environmental factors/circumstances or exposure, culminating in the combination of pain, frequency, urgency and sexual specific symptoms. New research has delineated the dynamic and powerful association of the immune and neurogenic system in pain activation. An immune-modulated neurogenic model of IC illuminating the action of immune derived substances and pain related substances might be important in discovering the determinants of pain, voiding dysfunction and gender specific sexual problems. This inter-related dynamic model of IC disease pathogenesis could be explored for potential avenues leading to novel diagnostic and treatment strategies. We plan to identify and evaluate the sensitivity and specificity of several novel nerve and inflammation related markers in the diagnosis and follow up of IC (and CP/CPPS). By correlating the levels of urine immune and pain related substances to disease mechanisms, severity and progression, we may be able to create a human disease specific model for diagnosis and treatment.

Conditions

  • Chronic Prostatitis With Chronic Pelvic Pain Syndrome
  • Chronic Bacterial Prostatitis
  • Asymptomatic Inflammatory Prostatitis
  • Painful Bladder Syndrome
  • Cystitis, Interstitial

Interventions

GENETIC

Genomic and proteomic biomarker discovery

Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods

Sponsors & Collaborators

Principal Investigators

  • Jordan D Dimitrakoff, MD, PhD · Harvard Medical School, Boston, MA

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00672087 on ClinicalTrials.gov